share_log

Will Weakness in WuXi AppTec Co., Ltd.'s (SHSE:603259) Stock Prove Temporary Given Strong Fundamentals?

Will Weakness in WuXi AppTec Co., Ltd.'s (SHSE:603259) Stock Prove Temporary Given Strong Fundamentals?

无锡药明康德有限公司会出现弱势吗鉴于基本面强劲,s(SHSE: 603259)股票被证明是暂时的?
Simply Wall St ·  04/25 20:18

WuXi AppTec (SHSE:603259) has had a rough three months with its share price down 37%. However, a closer look at its sound financials might cause you to think again. Given that fundamentals usually drive long-term market outcomes, the company is worth looking at. In this article, we decided to focus on WuXi AppTec's ROE.

药明康德(上海证券交易所代码:603259)经历了艰难的三个月,其股价下跌了37%。但是,仔细观察其良好的财务状况可能会让你重新考虑。鉴于基本面通常会推动长期市场业绩,因此该公司值得关注。在本文中,我们决定重点介绍药明康德的投资回报率。

Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. Simply put, it is used to assess the profitability of a company in relation to its equity capital.

股本回报率或投资回报率是用于评估公司管理层利用公司资本效率的关键指标。简而言之,它用于评估公司相对于其股权资本的盈利能力。

How Do You Calculate Return On Equity?

你如何计算股本回报率?

The formula for ROE is:

ROE 的公式是:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

股本回报率 = 净利润(来自持续经营业务)÷ 股东权益

So, based on the above formula, the ROE for WuXi AppTec is:

因此,根据上述公式,药明康德的投资回报率为:

17% = CN¥9.7b ÷ CN¥56b (Based on the trailing twelve months to December 2023).

17% = 97亿元人民币 ÷ 56亿元人民币(基于截至2023年12月的过去十二个月)。

The 'return' is the amount earned after tax over the last twelve months. So, this means that for every CN¥1 of its shareholder's investments, the company generates a profit of CN¥0.17.

“回报” 是过去十二个月的税后收入。因此,这意味着该公司每投资1元人民币,就会产生0.17元人民币的利润。

Why Is ROE Important For Earnings Growth?

为什么投资回报率对收益增长很重要?

So far, we've learned that ROE is a measure of a company's profitability. Depending on how much of these profits the company reinvests or "retains", and how effectively it does so, we are then able to assess a company's earnings growth potential. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features.

到目前为止,我们已经了解到,投资回报率是衡量公司盈利能力的指标。然后,我们能够评估公司的收益增长潜力,具体取决于公司对这些利润进行再投资或 “保留” 了多少及其有效性。假设其他条件都一样,与功能不相同的公司相比,具有更高股本回报率和更高利润保留率的公司通常具有更高的增长率。

WuXi AppTec's Earnings Growth And 17% ROE

药明康德的收益增长和17%的投资回报率

To begin with, WuXi AppTec seems to have a respectable ROE. Especially when compared to the industry average of 7.7% the company's ROE looks pretty impressive. This probably laid the ground for WuXi AppTec's significant 37% net income growth seen over the past five years. We reckon that there could also be other factors at play here. For instance, the company has a low payout ratio or is being managed efficiently.

首先,药明康德的投资回报率似乎相当不错。特别是与7.7%的行业平均水平相比,该公司的投资回报率看起来相当可观。这可能为药明康德在过去五年中实现37%的显著净收入增长奠定了基础。我们认为,这里可能还有其他因素在起作用。例如,该公司的派息率较低或管理效率很高。

We then compared WuXi AppTec's net income growth with the industry and we're pleased to see that the company's growth figure is higher when compared with the industry which has a growth rate of 23% in the same 5-year period.

然后,我们将药明康德的净收入增长与该行业进行了比较,我们很高兴地看到,与同期5年同期增长率为23%的行业相比,该公司的增长数字更高。

past-earnings-growth
SHSE:603259 Past Earnings Growth April 26th 2024
SHSE: 603259 过去的收益增长 2024 年 4 月 26 日

Earnings growth is an important metric to consider when valuing a stock. It's important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). This then helps them determine if the stock is placed for a bright or bleak future. If you're wondering about WuXi AppTec's's valuation, check out this gauge of its price-to-earnings ratio, as compared to its industry.

收益增长是对股票进行估值时要考虑的重要指标。对于投资者来说,重要的是要知道市场是否对公司的预期收益增长(或下降)进行了定价。然后,这可以帮助他们确定股票是面向光明还是暗淡的未来。如果你想知道药明康德的估值,可以看看这个衡量其市盈率与行业相比的指标。

Is WuXi AppTec Making Efficient Use Of Its Profits?

药明康德是否在有效利用其利润?

WuXi AppTec has a three-year median payout ratio of 28% (where it is retaining 72% of its income) which is not too low or not too high. By the looks of it, the dividend is well covered and WuXi AppTec is reinvesting its profits efficiently as evidenced by its exceptional growth which we discussed above.

药明康德的三年派息率中位数为28%(保留了收入的72%),这并不太低或不太高。从表面上看,股息覆盖范围很大,无锡AppTec正在有效地对其利润进行再投资,我们上面讨论的其出色增长就证明了这一点。

Besides, WuXi AppTec has been paying dividends over a period of five years. This shows that the company is committed to sharing profits with its shareholders. Our latest analyst data shows that the future payout ratio of the company over the next three years is expected to be approximately 25%. Accordingly, forecasts suggest that WuXi AppTec's future ROE will be 16% which is again, similar to the current ROE.

此外,药明康德已经在五年内派发了股息。这表明该公司致力于与股东分享利润。我们最新的分析师数据显示,公司未来三年的派息率预计约为25%。因此,预测表明,药明康德未来的投资回报率将为16%,与目前的投资回报率相似。

Summary

摘要

Overall, we are quite pleased with WuXi AppTec's performance. Particularly, we like that the company is reinvesting heavily into its business, and at a high rate of return. Unsurprisingly, this has led to an impressive earnings growth. With that said, the latest industry analyst forecasts reveal that the company's earnings growth is expected to slow down. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more.

总的来说,我们对药明康德的表现非常满意。特别是,我们喜欢该公司对其业务进行大量再投资,而且回报率很高。毫不奇怪,这带来了令人印象深刻的收益增长。话虽如此,最新的行业分析师预测显示,该公司的收益增长预计将放缓。要了解有关公司未来收益增长预测的更多信息,请查看这份关于分析师预测的免费报告,以了解更多信息。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发